NCT06379165

Efficacy and Safety Study of Meloxicam Nanocrystal Injection for the Treatment of Moderate to Severe Pain

Efficacy and Safety Study of Meloxicam Nanocrystal Injection for the Treatment of Moderate to Severe Pain After Abdominal Surgery - a Multicenter, Randomized, Double-blind, Placebo-parallel Controlled, Phase III Clinical Trial

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 192 (actual)
• Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of meloxicam nanocrystal injection in subjects with moderate to severe pain after abdominal surgery.

Detailed description

In this study, a randomized, double-blind, placebo-controlled multicenter study will be conducted to evaluate the efficacy and safety of meloxicam nanocrystal injection in subjects with moderate to severe pain after abdominal surgery.

Conditions

• Pain

Interventions

Type	Name	Description
DRUG	Meloxicam Nanocrystal Injection	30 mg (1 mL), once daily, by intravenous infusion
DRUG	Placebo	1 mL Placebo, once daily, by intravenous infusion

Timeline

• Start date: 2023-05-17
• Primary completion: 2023-07-11
• Completion: 2023-07-13
• First posted: 2024-04-23
• Last updated: 2024-04-23

Locations

1 site across 1 country: China